Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Basile, Lena A ^a   Gallaher, Timothy K ^b   Shibata, Darryl ^b   Miller, Joseph D ^b   Douer, Dan ^b  

^a Neumedicines Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMATOPOIESIS; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MALE; MOUSE; NONHUMAN; RADIATION DOSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; CANCER TRANSPLANTATION; CYTOLOGY; HEMATOPOIETIC STEM CELL; IMMUNOTHERAPY; LEWIS CARCINOMA; LUNG TUMOR; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; IMMUNOTHERAPY; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHOMA; MALE; MICE; NEOPLASM TRANSPLANTATION;

EID: 45549097962     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-26     Document Type: Article

References (69)

1. Bociek RG Armitage JO: Hematopoietic growth factors CA Cancer. J Clin 1996, 46(3):165-84. 10.3322/canjclin.46.3.165 8646546
2. Zagonel V Rupolo M Pinto A: Active protection from chemotherapy toxicity. Crit Rev Oncol Hematol 1998, 27(2):125-7. 10.1016/ S1040-8428(97)10017-8 9571312
3. Vahdat L Raptis G Fennelly D Crown J: High-dose chemotherapy of metastatic breast cancer: A review. Cancer Invest 1995, 13:505-10. 10.3109/07357909509024915 7552818
4. Awedan AA: High intensity regimens with autologous hematopoietic stem cell transplantation as a treatment for multiple myeloma. Ann Transplant 2002, 7:38-43. 12416471
5. Wang CH Wang HM Chen JS Chang WJ Lai GM: Intensive chemotherapy plus recombinant human granulocyte-colony-stimulating factor support for distant metastatic nasopharyngeal carcinoma: A preliminary report. Oncology 1997, 54:34-37. 8978590
6. Negoro S Masuda N Furuse K Saijo N Fukuoka M: Dose-intensive chemotherapy in extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1997, 40(Suppl):S70-73. 10.1007/s002800051065 9272138
7. Lemoli RM Rosti G Visani G Gherlinzoni F Miggiano MC Fortuna A Zinzani P Tura S: Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin 3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. J Clin Oncol 1996, 14:3018-25. 8918500
8. Neta R: Modulation of radiation damage by cytokines. Stem Cells 1997, 15(Suppl 2):87-94. 9368290
9. Fisher DC Peters WP: Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Curr Opin Hematol 1994, 1(3):221-7. 9371286
10. Veltri S Smith JW 2nd: Interleukin A trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 1996, 14(2):164-76. 8991536
11. Neidhart J Mangalik A Kohler W Stidley C Saiki J Duncan P Souza L Downing M: Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989, 7(11):1685-92. 2478670
12. Beck MN Beck D: Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 1995, 25(1):17-21. 10.1002/mpo.2950250105 7752997
13. Kurzrock R: Thrombopoietic factors in chronic bone marrow failure states: The platelet problem revisted. Clin Cancer Res 2005, 11(4):1361-1367. 10.1158/1078-0432.CCR-04-1094 15746033
14. Demetri GD: Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001, 6(Suppl 5):15-23. 10.1634/theoncologist.6-suppl_5-15 11700388
15. Gallicchio VS: Accelerated recovery of hematopoiesis following sublethal whole-body radiation with recombinant murine interleukin-1 (IL-1). J Leukocyte Biol 1988, 43:211-215. 3278072
16. Lynch DH Rubin AS Miller RE Williams DE: Protective effects of human recombinant IL-1α in doxorubicin-treated normal and tumor-bearing mice. Cancer Res 1993, 53:1565-70. 8453624
17. Tiberghien P Laithier V Mabed M Racadot E Reynolds CW Angorin R Loumi R Pavy JJ Cahn JY Noir A Herve P: Interleukin-1 administration before lethal irradiation and allogenic bone marrow transplantatation: Early transient increase of peripheral granulocytes and successful engraftment with accelerated leukocyte, erythrocyte and platelet recovery. Blood 1993, 81:1933-39. 8461477
18. Zsebo KM Smith KA Hartley CA Greenblatt M Cooke K Rich W McNiece IK: Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci USA 1992, 89:9464-68. 50152 1384054 10.1073/pnas.89.20.9464
19. Mouthon MA Meeren Van der Gaugler MH Visser TP Squiban C Gourmelon P Wagemaker G: Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body radiation. Int J Radiat Oncol Biol Phys 1999, 43(4):867-75. 10098443
20. Shibuya K Akahori H Takahashi K Tahara E Kato T Miyazaki H: Multilineage hematopoietic recovery by a single injection of megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998, 91:37-45. 9414267
21. Curti BD Smith JW: Interleukin-1 in the Treatment of Cancer. Pharmacol Ther 1995, 65(3):291-302. 10.1016/0163-7258(95)98595-H 7644565
22. McNiece IK Briddell BA: Stem Cell Factor. J Leukoc Biol 1995, 58:14-22. 7542304
23. Basser RL O'Flaherty E Green M Edmonds M Nichol J Menchaca DM Cohen B Begley GC: Development of pancytopenia with neutralizing antibodies to thrombopoietiin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002, 99:2599-2602. 10.1182/ blood.V99.7.2599 11895799
24. Colombo MP Trinchieri G: Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13(2):155-168. 10.1016/ S1359-6101(01)00032-6 11900991
25. Brunda MJ Luistro L Warrier RR Wright RB Hubbard BR Murphy M Wolf SF Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-30. 2191194 8104230 10.1084/jem.178.4.1223
26. Smyth MJ Taniguchi M Street SE: The anti-tumor activity of IL-12 mechanisms of innate immunity that are model and dose dependent. J Immunol 2000, 165:2665-70. 10946296
27. Gillary Segak J Lee NC Tsung YL Norton JA Tsung K: The role of interferon-γ in rejection of established tumors by IL-12: Source of production and target. Cancer Res 2002, 62:4696-4703. 12183428
28. O'Donnell MA Luo Y Hunter SE Chen X Hayes LL Clinton SK: Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: Dose dependent tumor eradication and generation of protective immunity. J Urol 2004, 171(3):1330-35. 10.1097/01.ju.0000109742.88380.a2 14767343
29. Mandpe AH Tsung K Norton JA: Cure of an established non-immunogenic tumor, SCC VII, with a novel Interleukin 12-based immunotherapy regimen in CH3 mice. Arch Otolaryngol Head & Neck Surg 2003, 129:786-792. 10.1001/archotol.129.7.786 12874083
30. Leonard JP Sherman ML Fisher GL Buchanan LJ Larsen G Atkins MB Sosman JA Dutcher JP Vogelzang NJ Ryan JL: Effects of single-dose Interleukin-12 exposure on Interleukin-12-associated toxicity and interferon-γ production. Blood 1997, 90:2541-48. 9326219
31. Bellone G Trinchieri G: Dual stimulatory and inhibitory effect of NK Cell Stimulatory Factor/IL-12 on human hematopoiesis. J Immunol 1994, 153:930-37. 7517976
32. Neta R Stiefel SM Finkelman F Herrmann S Ali N: IL-12 protect bone marrow from and sensitized intestinal tract to ionizing radiation. J Immunol 1994, 153:4230-37. 7930625
33. Jacobsen SE Veiby OP Smeland EB: Cytotoxic lymphocyte maturation factor (Interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 1993, 178:413-18. 2191103 7688022 10.1084/jem.178.2.413
34. Ploemacher RE van Soest PL Boudewijn A Neben S: Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor. Leukemia 1993, 7:1374-80. 7690439
35. Jackson JD Yan Y Brunda MJ Kelsey LS Talmadge JE: Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995, 85:2371-76. 7727771
36. Chen T Burke KA Zhan Y Wang X Shibata D Zhao Y: IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007, 35:203-13. 10.1016/ j.exphem.2006.10.002 17258069
37. Plasencia C Dayam R Wang Q Pinski J Burke TR Quinn DI Neamati N: Discovery and preclinical evaluation of a novel class of small molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther 2005, 4:1105-13. 10.1158/1535-7163.MCT-04-0288 16020668
38. Tumor Models in Cancer Research. Cancer Drug Discovery and Development, Humana Press Beverly A Teicher 2002:10-60.
39. Center for Biological Sequence Analysis (CBS) prediction server http://www.cbs.dtu.dk/services
40. Steidl U Fenk R Bruns I Neumann F Kondakci M Hoyer B Gräf T Rohr UP Bork S Kronenwett R Haas R Kobbe G: Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005, 35(1):33-6. 10.1038/sj.bmt.1704702 15531906
41. Lee JK Back TC Komschlies KL Ruscetti FW Young HA Wiltrout RH: Hematopoietic switch from lymphoid to granulocytic development n 3LL tumor-bearing mice. In Vivo 2001, 15:255-63. 11695215
42. Fulop G Lee MY Rosse C: A granulocytosis-induing tumor inhibits the production of B lymphocytes in murine bone marrow. J Immunol 1985, 135:4266-4272. 3877765
43. Serafini P De Santo C Marigo I Cingarlini S Dolcetti L Gallina G Zanovello P Bronte V: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004, 53:64-72. 10.1007/ s00262-003-0443-2 14593498
44. Hocking W Goodman J Golde D: Granulocytosis associated with tumor cell production of colony-stimulating activity. Blood 1983(61):600-603. 6600635
45. Omura N Sadanobu A Hirai K Aoki T: A case of granulocyte-colony stimulationg factor producing gallbladder cancer. Am J Gastroenterol 1999, 94:273-74. 10.1111/j.1572-0241.1999.00817.x 9934773
46. Prechel MM Lozano Y Wright MA Ihm J Young MR; Ineffective immune enhancement by IL-12 in tumor-bearing mice whose immune depression is mediated by suppressive granulocyte-macrophage progenitor cells. Cancer Lett 92(2):235-42. 1995 Jun 8 10.1016/0304-3835(95)03804-6 7600536
47. Mapara MY Sykes M; Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-51. 10.1200/JCO.2004.10.041 15020616
48. DeGowin RL Gibson DP Knapp SA; Tumor bearing impairs hematopoietic recovery and survival after radiation. Exp Hematol 1983, 11(4):305-1. 6341078
49. Kovacs CJ Gooya JM Harrell JP McGowan KM Evans MJ: Altered radioprotective properties of interleukin I alpha (IL-1) in non-hematologic tumor-bearing animals. Int J Radiat Oncol Biol Phys 1991, 20:307-10. 1991693
50. Bellone G Turletti A Artusio E Mareschi K Carbone A Tibaudi D Robecchi A Emanuelli G Rodeck U: Tumor-associated transforming growth factor β and Interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999, 155:537-46. 1866873 10433946
51. Zou JP Morford LA Chougnet C Dix AR Brooks AG Torres N Shuman JD Cokigan JE Brooks WH Roszman TL Shearer GM: Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999, 162:4882-92. 10202033
52. Mouri H Sakaguchi K Sawayama T Senoh T Ohta T Nishimura M Fujiwara A Terao M Shiratori Y Tsuji T: Suppressive effects of transforming growth factor β produced by hepatocellular carcinoma cell lines on interferon γ production by peripheral blood mononuclear cells. Acta Med Okayama 2002, 56(6):309-15. 12685860
53. Genomics Institute of the Novartis Research Foundation http://symatlas.gnf.org
54. Ida M Kusaka M Kato T Miyazaki H Kabaya K Akahori H Shibuya K Nitta Y: In vivo effect of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells 1996, 14:651-60. 8948023
55. Skomorovski K Harpak H Ianovski A Vardi M Visser TP Hartong SCC van Vliet HHDM Wagemaker G Agur Z New TPO: Treatment schedules of increased safety and efficacy: Pre-clinical validation of a thrombopoiesis simulation model. Br J Haematol 2003, 123:683-91. 10.1046/ j.1365-2141.2003.04696.x 14616973
56. Pestina TI Cleveland JL Yang C Zambetti GP Jackson CW: Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood 2001, 98:2084-90. 10.1182/blood.V98.7.2084 11567994
57. Schwarz A Ständer S Berneburg M Böhm M Kulms D van Steeg H Grosse-Heitmeyer K Krutmann J Schwarz T: Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002, 4:26-31. 10.1038/ncb717 11780128
58. Schwarz A Maeda A Kernebeck K van Steeg H Beissert S Schwarz T: Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med 2005, 201:173-9. 2212783 15657287 10.1084/jem.20041212
59. Meeran SM Mantena SK Katiyar SK: Prevention of ultraviolet radiation-induced immunosuppression by (-)-epigallocatechin-3-gallate in mice is mediated through interleukin 12-dependent DNA repair. Clin Cancer Res 2006, 12:2272-80. 10.1158/1078-0432.CCR-05-2672 16609044
60. Car BD Eng VM Lipman JM AndeAson TD: The toxicology of interleukin-12: a review. Toxicol Pathol 1999, 27:58-63. 10.1177/019262339902700112 10367675
61. Car BD Eng VM Schnyder B LeHir M Shakhov AN Woerly G Huang S Aguet M Anderson TD Ryffel B: Role of interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol 1995, 147:1693-707. 1869961 7495294
62. Eng VM Car BD Schnyder B Lorenz M Lugli S Aguet M Anderson TD Ryffel B Quesniaux VF: The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J Exp Med 1995, 181:1893-8. 2191982 7722464 10.1084/jem.181.5.1893
63. Little RF Aleman K Kumar P Wyvill KM Pluda JM Read-Connole E Wang V Pittaluga S Catanzaro AT Steinberg SM Yarchoan R: IL-12 and liposomal doxorubicin for Kaposi's sarcoma. Blood 2007, 110(13):4165-71. 10.1182/ blood-2007-06-097568 17846226
64. Demaria S Bhardwaj N McBride WH Formenti SC; Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 2005, 63(3):655-66. 1489884 16199306
65. Yasuda A Sawai H Takahashi H Ochi N Matsuo Y Funahashi H Sato M Okada Y Takeyama H Manabe T: The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 2006, 5:46. 1634869 17044945 10.1186/1476-4598-5-46
66. Quentmeier H Zaborski M Graf G Ludwig WD Drexler HG: Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. Leukemia 1996, 10:297-310. 8637239
67. U.S. Food and Drug Administration: Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. FDA Alert 2:16 2007 http://www.fda.gov/cder/drug/infopage/RHE/default.htm
68. Henke M Laszig R Rübe C Schäfer U Haase KD Schilcher B Mose S Beer KT Burger U Dougherty C Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1225-1260. 10.1016/S0140-6736(03)14567-9 14568747
69. Leyland-Jones B Semiglazov V Pawlicki M Pienkowski T Tjulandin S Manikhas G Makhson A Roth A Dodwell D Baselga J Biakhov M Valuckas K Voznyi E Liu X Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005, 23(25):5960-5972. 10.1200/JCO.2005.06.150 16087945